FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					-															
1. Name and Address of Reporting Person* STEER RANDOLPH C						2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
STEER RAINDOLPH C						BCRX 1									Directo	r		10% Ow	ner	
(Last) (First) (Middle) 2190 PARKWAY LAKE DR						•										Officer (give title		Other (s	pecify	
								Trans	saction (M	onth/	Day/Year)			below)	below)		below)			
						05/11/2005														
(Street)				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
BIRMINGHAM AL 35244			35244											X	Form fi	led by One	Report	ting Persor	1	
					-										Form filed by More than One Reporting					
(City) (State) (Zip)													Person							
		Tal	ble I - Nor	n-Deriv	vativ	<u>α</u> ς _α	curitio	- Δc	nuired	Die	nosed o	f or Re	nefic	ially	Owned					
			oic i - ivoi	_					3.	D 13	-				5. Amour				. Nature of	
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						ear)	2A. Deemed Execution Date if any (Month/Day/Yea		r, Transaction Disposed Code (Instr. 5)			ties Acquired (A) o I Of (D) (Instr. 3, 4 a		Securitie Beneficia Owned F		s For	6. Own Form: I (D) or I: (I) (Inst	Direct I	Indirect Beneficial Ownership	
									Code V		Amount	(A) or	Pric	ce	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
										<u> </u>					1,	ina 4)				
			Table II -								osed of, convertib				wned					
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deeme Execution I if any (Month/Day	Date,	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)			3. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	y [0	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amor or Numl of Share	ber						
Stock Option	\$4.3	05/11/2005	05/11/20	05	A		10,000		06/11/200	5(1)	05/11/2015	Common Stock	10,0	000	\$4.3	90,000		D		

Explanation of Responses:

1. Vest at 1/12 of total grant from grant date.

Remarks:

Michael Richardson

05/13/2005

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.